GHRS earnings: real EPS beat/miss history, analyst consensus Buy, P/E -31.07. Updated 2026-07-23.
GH Research (GHRS) Research Hub
GH Research (GHRS) trades on NASDAQ, IE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 27.2 USD (-1.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -31.07, market cap 1.95B. This hub links to the full technical, earnings and options research available for GHRS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IE |
| Last close | 27.2 USD (-1.31%) |
| 52-week range | 19.96 USD – 31.44 USD |
| Trend regime | Range |
| 14-day RSI | 34.3 (Bearish) |
| Trailing P/E | -31.07 |
| Market cap | 1.95B |
| Dividend yield | 0.00% |
Available research for GHRS
Covered Call on GHRS: how it works, illustrative setup around the real 27.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GHRS: how it works, illustrative setup around the real 27.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GHRS: how it works, illustrative setup around the real 27.2 USD price, max profit/loss, breakeven and when to use it. Educational.
GHRS technical analysis: range, last 27.2 USD, RSI 34.3, 52w range 19.96 USD–31.44 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GHRS in?
GH Research (GHRS) is classified under Healthcare (Biotechnology), listed on NASDAQ, IE.
Is GHRS in an uptrend or downtrend?
As of 2026-09-11, GHRS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GHRS's trailing P/E ratio?
GHRS's trailing P/E is -31.07, with a market cap of 1.95B. See the earnings research page for full valuation detail.